Interax Biotech

InterAx is redefining drug discovery by understanding treatment impact on diseases before pre-clinical trials begin, an analysis traditionally inaccessible to very early programs. Focusing on GPCR small molecules, the Deep Signal™ platform enables superior optimization of drug candidates, leading to differentiated drugs with higher efficacy and safety and lower clinical failure rates. InterAx’s three-asset portfolio demonstrates this impact, including a biologically differentiated GLP-1 asset that addresses the challenges seen with small-molecule competitors, a partnered GIP program, as well as an innovative ACKR3 program driven by unique target understanding. With four additional targets identified, the company is poised to expand into neurologic and autoimmune indications. Growing asset and platform partnerships highlight strong market traction, with future investments set to unlock GLP-1 value and scale the portfolio.